Products for Research Use Only

ABT-866

CAT: 0804-HY-119262Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-119262Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ABT-866 is an α1A-adrenoceptor agonist and an antagonist at the α1B- and α1D-adrenoceptor subtypes. ABT-866 has an EC50 of 0.60 μM for the α1A in the rabbit urethra. ABT-866 has a pA2 value of 5.4 for the α1B in the rat spleen. ABT-866 has a pA2 value of 6.2 for the α1D in the rat aorta. ABT-866 exhibits good urethral selectivity and lower cardiovascular side effects in stress urinary incontinence models. ABT-866 can be used for the research of diseases such as stress urinary incontinence[1][2].
CAS Number
258526-74-8
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Adrenergic Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Cardiovascular Disease
Smiles
O=S(NC1=CC=CC(CC2=CN=CN2)=C1)(CC)=O
Molecular Formula
C12H15N3O2S
Molecular Weight
265.33
Precautions
P261-P280-P302+P352
References & Citations
[1]Buckner SA, et al. ABT-866, a novel alpha (1A) -adrenoceptor agonist with antagonist properties at the alpha (1B) - and alpha (1D) -adrenoceptor subtypes. Eur J Pharmacol. 2002 Aug 2;449 (1-2) :159-65.|[2]Altenbach RJ, et al. N-[3- (1H-imidazol-4-ylmethyl) phenyl]ethanesulfonamide (ABT-866, 1), (1) a novel alpha (1) -adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J Med Chem. 2002 Sep 26;45 (20) :4395-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1